Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study to investigate the safety, tolerability, immunogenicity and efficacy of HTI T-cell vaccine and vesatolimod in HIV-infected individuals on antiretroviral therapy.

Trial Profile

A clinical study to investigate the safety, tolerability, immunogenicity and efficacy of HTI T-cell vaccine and vesatolimod in HIV-infected individuals on antiretroviral therapy.

Planning
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2018

At a glance

  • Drugs HTI immunogen (Primary) ; Vesatolimod (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms AELIX-003
  • Most Recent Events

    • 26 Oct 2018 New trial record
    • 18 Oct 2018 According to an Aelix Therapeutics media release, the initiation of AELIX-003 is targeted for early 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top